Latest Biotech & Health Tech
News & Analysis

China isn’t willing to sit back while the U.S. pushes ahead in brain tech. A Chinese company called Neuracle Technology now has regulatory clearance to sell an invasive brain implant.  China isn’t willing to sit back while the U.S. pushes ahead in brain tech. A Chinese company called Neuracle Technology now has regulatory clearance to sell an invasive brain implant.  

Amazon Health AI is now appearing in front of hundreds of millions of shoppers as Amazon places an AI medical assistant directly inside its core shopping app.

Bristol Myers Squibb (BMY) just pulled an overlooked cancer drug back into focus. Its experimental drug mezigdomide improved progression free survival in patients with late stage multiple myeloma. 

Novo Nordisk (NVO) Hims & Hers (HIMS) partnership talks are back on the table after months of public conflict over weight-loss drugs. Great for HIMS. But not so much for NVO.

What if the next AI chip won't be made from silicon, but human brain cells. Scientists in Australia just proved this is possible. Then grew human brains in a lab. Then had it play Doom.

Amazon (AMZN) plans to use AI agents to take over the mountain of administrative work that sits behind every doctor visit. It could be a huge win for the US healthcare system.

Your morning coffee might one day do more than wake you up. It could help control CRISPR gene editing inside the human body.

Nvidia (NVDA) just pushed AI cancer detection and computing into a place it’s never really been before: the hospital decision room.

2026 could be the year gene editing shifts from science proof to delivery scale. The constraint isn’t if CRISPR works, it’s cost, manufacturing capacity, and hospital readiness to treat patients.

A 19 year old from Kelowna just beat a lethal genetic disease using a one time gene edit.

Quantum computing in healthcare is mostly about drugs, not doctors. It helps when you’re simulating nature, not paperwork. And it’s arriving as a hybrid add-on, not a full replacement.

Novo Nordisk (NVO) stock is falling again, and this time it’s not about demand, but about price. Novo Nordisk plans to cut the price of Wegovy. That’s a big deal.

Novo just blinked in the $100 billion obesity drug war. Lilly now has the stronger weapon, and Wall Street noticed instantly. This isn’t a trial miss, but a power shift.

Masimo (MASI) stock jumped 34% after Danaher (DHR) agreed to buy the company for $9.9B in cash, offering $180 per share.

Novo Nordisk (NVO) just sued Hims & Hers (HIMS) for selling copycat versions of Wegovy. The health-tech war continues and the market answered fast. 

Hims stock slid after the company pulled its $49 GLP-1 pill following an FDA warning that it would rapidly enforce laws against copycat drugs.

Novo Nordisk (NVO) stock can recover. But it won’t look like the last run. The last two weeks reminded everyone that even disruptors can get disrupted.

Novo Nordisk (NVO) stock slides again after Hims & Hers Health (HIMS) rolled out a compounded semaglutide weight loss pill priced to shock the system. 

Health tech giant Eli Lilly (LLY) just told the market what actually matters for its obesity pill launch. Medicare is coming in at the door, day one.

Health tech company AstraZeneca (AZN) just signed a licensing deal worth up to $18.5 billion to access Made-in-China obesity drugs from China’s CSPC Pharmaceutical Group.